373 related articles for article (PubMed ID: 30176844)
1. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.
Ijaz S; Bolea B; Davies S; Savović J; Richards A; Sullivan S; Moran P
BMC Psychiatry; 2018 Sep; 18(1):275. PubMed ID: 30176844
[TBL] [Abstract][Full Text] [Related]
2. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
Aly El-Gabry DM; Abdel Aziz K; Okasha T; Azzam H; Okasha A
J Clin Psychopharmacol; 2018 Feb; 38(1):27-33. PubMed ID: 29210867
[TBL] [Abstract][Full Text] [Related]
5. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.
Jeon SW; Kim YK
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29057817
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
7. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
Fleischhacker WW; Uchida H
Int J Neuropsychopharmacol; 2014 Jul; 17(7):1083-93. PubMed ID: 22717078
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.
Azorin JM; Simon N
Expert Opin Drug Metab Toxicol; 2020 Dec; 16(12):1175-1186. PubMed ID: 32930009
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink.
Eyles E; Margelyte R; Edwards HB; Moran PA; Kessler DS; Davies SJC; Bolea-Alamañac B; Redaniel MT; Sullivan SA
Schizophr Bull; 2024 Mar; 50(2):447-459. PubMed ID: 37622178
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
Lähteenvuo M; Tiihonen J
Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
[TBL] [Abstract][Full Text] [Related]
11. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Stahl SM; Grady MM
Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
14. Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy.
Sugai T; Suzuki Y; Yamazaki M; Sugawara N; Yasui-Furukori N; Shimoda K; Mori T; Ozeki Y; Matsuda H; Okamoto K; Sagae T; Someya T
J Clin Psychopharmacol; 2020; 40(1):14-17. PubMed ID: 31834097
[TBL] [Abstract][Full Text] [Related]
15. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
18. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
Vuk A; Kuzman MR; Baretic M; Osvatic MM
Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569
[TBL] [Abstract][Full Text] [Related]
19. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
